Needham analyst Gil Blum maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today and set a price target of $75.00. The company's shares closed last Thursday at $10.00, close to its 52-week low of $9.81. According to TipRanks.com, Blum has 0 stars on 0-5 stars ranking scale with an average return of -39.7% and a 7.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Crispr Therapeutics AG. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rocket Pharmaceuticals with a $66.50 average price target.
https://www.tipranks.com/news/blurbs/needham-thinks-rocket-pharmaceuticals-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Rocket Pharmaceuticals Charts.
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Rocket Pharmaceuticals Charts.